Helping to realize data-driven, personalized care that treats patients based on their unique genomic characteristics across therapeutic areas.
We are rapidly moving towards individualized treatments and disease interventions that will change how we care for people around the world.
For years, patients diagnosed with a disease often received the same treatment. And for some people, that treatment worked. However, for others, it did not at all work – or only marginally or with serious side effects. This meant that, on average, only 50% of patients benefited from their treatment. With the mapping of the genome in combination with new, analytical scientific and technological advances, we can now develop personalized treatments for individuals or patient populations.
Huge advances in areas like cell and gene therapy, specifically in oncology and rare diseases are changing the treatment landscape. We conducted research to understand the key trends in precision oncology and how leaders are responding.
It’s our privilege to be working with the most progressive life sciences companies to bring precision medicine to people around the world.
Precision medicine holds great promise for reshaping the way we treat cancer, yet research shows that there are hurdles before realizing its full potential.
$2M
For the most expensive precision medicine today.1
700
New cancer drugs are currently in late-stage development, and over 90% of these are targeted therapies.2
67%
Increase in the number of active agents in the global immuno-oncology pipeline.3
1 Financial Times, 2019
2 The IQVIA Institute, 2018
3 Cancer Research Institute, 2019
We bring capabilities from early research through full commercialization in combination with deep technology and digital expertise to help our clients deliver personalized healthcare to their patients.
Bringing our deep precision medicine expertise to help clients design and build drug development for shifting manufacturing and commercial operations.
Shaping and designing industry-leading patient and healthcare professional experiences and services with our business service design arm Fjord.
Leveraging our data science expertise: accelerate R&D, enable clinically relevant biomarkers, action patient care analytics along their lifespan.
Aggregating, analyzing and actioning patient data and insight from across their healthcare and everyday experience using architectures and platforms, including INTIENT.
Cell and Gene Therapy (CGT) is growing in the fight against cancer and other diseases. We help our clients address the patient, product and value chain for CGT which requires new and specialized sets of capabilities.
3
Working with clients in all three commercially approved CGT therapies.
13
Active clients in CGT globally.
3
We are helping clients across three areas: R&D, supply chain and patient engagement.
BioPharma is in disruption. See how leaders are using New Science to compete in the current healthcare landscape
A survey of 40 biopharma CEOs and their marketing leaders on creating customer relevance through building an agile, living marketing organization.
What can Pharma Cos do differently when launching new innovative products for precision medicine and personalized healthcare?
Accenture helped a biopharma company implement a patient-centered platform to manage the delivery of a personalized gene therapy solution.
With data integration provided by Accenture, Roche's NAVIFY® Tumor Board is changing the way tumor board meetings are organized and conducted.
A biopharmaceutical company collaborates with Accenture to navigate a complex FDA submission for an innovative cell therapy.
Cell and gene therapy (CGT) is not just hype. We’re seeing real progress in the fight against cancer and other diseases.
First in a two-part series on overcoming challenges in cell and gene therapy.
Second in a two-part series on overcoming challenges in cell and gene therapy.
filter result
